Firefighter #CheckYourFoodTube Precancer
Testing Event organized by Mass General Brigham physicians and
Boston Firefighters Local 718 IAFF
NEW
YORK, June 12, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and majority-owned subsidiary of PAVmed Inc.
(Nasdaq: PAVM), today announced that the 4,000th
firefighter has undergone esophageal precancer testing using
Lucid's EsoGuard® Esophageal DNA test as part
of a #CheckYourFoodTube Precancer Testing Event. In partnership
with physicians from Mass General Brigham, Boston's Local 718 International Association
of Fire Fighters (IAFF) hosted its first #CheckYourFoodTube event
to ensure its at-risk firefighters could be tested for esophageal
precancer. This milestone coincided with Esophageal Cancer
Awareness Month and highlighted the proactive steps being taken by
the broader firefighter community to address the elevated risk of
cancer in firefighters.
"Early detection and preventative screenings are paramount in
ensuring the health and safety of everyone, but especially
firefighters," said Sam Dillon,
Boston Firefighters Local 718 IAFF President. "There is a startling
number of firefighters being diagnosed with and dying from
esophageal cancer, and the EsoGuard test from Lucid Diagnostics is
able to detect precancer signals and allow firefighters like me to
go through treatment before actually developing cancer. I strongly
encourage all firefighters to take advantage of the
#CheckYourFoodTube esophageal precancer screening events, as I
did."
"This was our 105th #CheckYourFoodTube event
and represents an important milestone for our EsoGuard commercial
efforts," added Shaun O'Neil,
Lucid's President and Chief Operating Officer. "We continue
to build out a robust pipeline of these events which have been a
key component of our overall strategy to drive test volume. We are
grateful for the opportunity to help firefighters like Sam Dillon and other members of Boston
Firefighters Local 718 identify esophageal precancer before it
becomes a lethal reality for them. We would like to thank
Kumar Krishnan, M.D. and
Alexandra Maltby of Mass General
Brigham for facilitating this #CheckYourFoodTube event, and
UpScriptHealth for powering telemedicine consultations for this and
other events."
Firefighters have a 62% increased risk of developing esophageal
cancer, and a 39% increased risk of dying from the same, according
to the Firefighter Cancer Support Group. It is estimated that there
will be 22,370 new cases of esophageal cancer in 2024, and that
16,130 people will die this year from this disease, according to
the American Cancer Society.
To learn more about hosting a #CheckYourFoodTube Precancer
Testing Event, please visit www.esoguard.com/request-an-event.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device - the first
and only commercially available tools designed with the goal of
preventing cancer and cancer deaths through widespread, early
detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes
forward-looking statements that involve risk and uncertainties.
Forward-looking statements are any statements that are not
historical facts. Such forward-looking statements, which are based
upon the current beliefs and expectations of Lucid Diagnostics'
management, are subject to risks and uncertainties, which could
cause actual results to differ from the forward-looking statements.
Risks and uncertainties that may cause such differences include,
among other things, volatility in the price of Lucid Diagnostics'
common stock; general economic and market conditions; the
uncertainties inherent in research and development, including the
cost and time required to advance Lucid Diagnostics' products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid Diagnostics'
clinical and preclinical studies; whether and when Lucid
Diagnostics' products are cleared by regulatory authorities; market
acceptance of Lucid Diagnostics' products once cleared and
commercialized; Lucid Diagnostics' ability to raise additional
funding as needed; and other competitive developments. These
factors are difficult or impossible to predict accurately and many
of them are beyond Lucid Diagnostics' control. In addition, new
risks and uncertainties may arise from time to time and are
difficult to predict. For a further list and description of these
and other important risks and uncertainties that may affect Lucid
Diagnostics' future operations, see Part I, Item 1A, "Risk
Factors," in Lucid Diagnostics' most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as the same
may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly
Report on Form 10-Q filed by Lucid Diagnostics after its most
recent Annual Report. Lucid Diagnostics disclaims any
intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in its expectations
or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that
actual results will differ from those contained in the
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/4-000th-firefighter-undergoes-lucid-diagnostics-esoguard-esophageal-precancer-testing-302170682.html
SOURCE Lucid Diagnostics